Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.65 in the quarter versus EPS of $-0.23 in the year-earlier quarter. Revenue Rose 35.12% to $19.43 million from the year-earlier quarter.
Optimer Pharmaceuticals, Inc. reported adjusted EPS loss of $0.65 per share. By that measure, the company missed the mean analyst estimate of $-0.42. It missed the average revenue estimate of $21.09 million.